✅ Subscribe Open Now SME IPO BSE SME Packaging

Injecto Polymers IPO

₹56.12 Cr · Fresh Issue · Packaging

Price Band
₹98
Lot: 1200 shares (₹117,600)
GMP (Grey Market)
No GMP data yet
Issue Size
₹56.12 Cr
Fresh Issue
Market Cap
₹207.90 Cr
At upper band
P/E Ratio
9.48x
Listing Date
21st Sep 2026
BSE & NSE
IPO Timeline
Opens
11th Sep 2026
Closes
16 Sep 2026
📋
Allotment
17 Sep 2026
Refund
18 Sep 2026
📈
Listing
21st Sep 2026
📄 Official Docs RHP (Red Herring Prospectus) ↗ DRHP ↗
Our Analysis — Key Points
✓ Strength
Exceptional revenue and profit growth
Revenue grew from ₹109.8 Cr (FY-2) to ₹375.8 Cr (FY0), a 2-year CAGR of 85%, while net profit surged 89.9% over the same period. This demonstrates strong operational leverage and market traction in the packaging sector, with FY0 net profit reaching ₹16.0 Cr.
✓ Strength
Deeply discounted valuation vs peers
At 9.48× P/E, the company trades at just 0.41× the niche/unlisted sector midpoint of 23×, offering substantial margin of safety. Even accounting for 4.3% NPM, the valuation provides significant upside potential if the company sustains growth momentum.
⚠ Risk
High leverage limits financial flexibility
Debt-to-equity ratio of 2.61× is materially above the 1.5× comfort threshold and constrains the balance sheet. While the IPO will repay ₹10 Cr of borrowings, the company will still carry substantial debt relative to equity post-issue.
⚠ Risk
Thin net profit margins pressure sustainability
NPM of 4.3% is well below the 15% threshold that would justify premium valuations, indicating limited pricing power or high input costs in the packaging business. Any margin compression from raw material inflation or competitive pressure could materially impact profitability.
₹ Valuation
Valuation significantly below sector norms
At 9.48× P/E versus a niche sector midpoint of 23×, the company is priced at 0.41× midpoint—well within the Subscribe threshold of ≤1.0×. The valuation reflects a 59% discount to sector average, offering asymmetric risk-reward for growth investors.
👁 Watch
Monitor debt reduction and margin trajectory
Track quarterly debt paydown progress and whether NPM expands toward 6–8% as the company scales. Failure to improve margins or a reversal in revenue growth would signal deteriorating fundamentals despite the attractive entry valuation.
Top Analyst Reviews
Analyst / Firm Rating Known For Review
IPO India Hub
Our independent review
Subscribe Original analysis based on DRHP & public financials This page
Dilip Davda
Chittorgarh.com
See review India's most followed independent IPO analyst Search on Chittorgarh →
Capital Market (CM Rating)
CapitalMarket.com
See review Widely-cited "New Issue Monitor" reports Search on CapitalMarket →
ICICI Securities
ICICIdirect Research
See review SEBI-registered broker research desk Visit ICICIdirect →
IPO Guru Analyst Leaderboard
ipoguru.in
See rankings Ranks 49 analysts by real IPO outcome accuracy View leaderboard →

External links go to each platform's IPO section — search for "Injecto Polymers" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.

Company Snapshot
Revenue ₹375.83 Cr
Net Profit ₹16.01 Cr
Industry Packaging
Issue Type Fresh Issue
Frequently Asked Questions
SPONSORED

Start Investing in IPOs Today

Open a free demat account in minutes. Apply for mainboard & SME IPOs with India's most trusted brokers.

5 Cr+ Clients
Z
Zerodha
India's Largest Broker
  • ₹0 brokerage on delivery
  • 1-click IPO apply on Kite
  • Instant UPI mandate block
Open Free Account →
Zero Brokerage
F
Fyers
Tech-First Broker
  • Free delivery trades
  • Supports NSE & BSE SME IPOs
  • Clean UI, fast application
Open Free Account →
Modern Platform
U
Upstox
Fast & Simple
  • Instant UPI mandate setup
  • Real-time allotment alerts
  • Simplified IPO flow
Open Free Account →

* Affiliate links. Opening an account is free. We may earn a commission at no extra cost to you.